13G Filing: Great Point Partners and Adamas Pharmaceuticals Inc (ADMS)

Page 5 of 8 – SEC Filing

CUSIP
No.  00548A106
13G/A Page
5 of 7 Pages

Item 1.

(a) Name
of Issuer
Adamas Pharmaceuticals Inc.
(b) Address of Issuer’s
Principal Executive Offices
1900 Powell St., Suite 750, Emeryville, CA 94608

Item 2.

(a) Name of Person Filing
Great Point Partners, LLC
Dr. Jeffrey R. Jay, M.D.
Mr. David Kroin
The Reporting Persons have entered into a Joint Filing Agreement, dated October 10, 2017, a copy of which is filed with this Schedule 13G/A as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.
(b) Address of Principal Business Office, or if none, Residence
The address of the principal business office of each of the Reporting
Persons is
165 Mason Street, 3rd Floor
Greenwich, CT 06830
(c) Citizenship
Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. David Kroin is a citizen of the United States.
(d) Title of Class of Securities
Common Stock
(e) CUSIP Number
00548A106
Item
3.
If
this statement is filed pursuant to §240.13d-1(b) or 240.13d.2(b) or (c), check whether the person filing is a:
(a) o Broker or dealer registered under Section 15 of the Act
(15 U.S.C. 78o)
(b) o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) o Insurance company as defined in Section 3(a)(19) of the Act (15. U.S.C.
78c).
(d) o Investment Company registered under Section 8 of the Investment Company
Act of 1940 (15 U.S.C. 80a-8).
(e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
(f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

Follow Adamas Pharmaceuticals Inc (NASDAQ:ADMS)